Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line Irinotecan and Capecitabine vs Irinotecan in Advanced Biliary Tract Cancer
NCT02558959Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in biliary tract cancer (BTC) (2 arms), sponsored by Zhejiang University. Primary endpoint: Progression Free Survival at 1 year. Started Sep 2015; status: completed.
02
Drugs
capecitabine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02558959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558959.